Navigation Links
Savient Announces the Election of Robert G. Savage to its Board of Directors
Date:12/5/2012

BRIDGEWATER, N.J., Dec. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to the Company's Board of Directors, effective December 5, 2012.

"Bob is a proven leader with an exceptional track record of success, and we are fortunate to have a pharmaceutical executive with such a wealth of experience join our Board of Directors," stated Stephen O. Jaeger, Chairman of Savient's Board of Directors.

Mr. Savage is currently President and CEO of Strategic Imagery LLC, a consulting company of which he is the principal.  Previously, Mr. Savage was Group Vice President and President of the Worldwide General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003.  Prior to that role, he held several senior positions with Johnson & Johnson, including Worldwide Chairman of the Pharmaceuticals Group, Company Group Chairman for the North American pharmaceuticals business, President of Ortho-McNeil Pharmaceuticals and Vice President of Sales and Marketing. Earlier in his career, he served in a variety of senior marketing, operations, business development and strategic planning positions for Hoffmann-La Roche, Inc.  Mr. Savage currently serves as a director of EpiCept Corporation, Nuovo Biologics and The Medicines Company.  Mr. Savage received a B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.

"Given Bob's extensive experience in domestic and international marketing, business development and operations, we are confident that he will immediately prove to be an invaluable addition to the board and as an advisor to our senior management team especially in light of the anticipated approval and launch of KRYSTEXXA® in the EU," said Lou Ferrari, President and Chief Executive Officer of Savient.  "His strategic vision and expertise in orchestrating major product launches with renowned success will be instrumental to Savient's ongoing commitment to providing KRYSTEXXA as a treatment option to patients suffering from refractory chronic gout (RCG) in the U.S. and around the world." 

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com

SVNT - GContact:Savient Pharmaceuticals, Inc.

Burns McClellan John P. Hamill

Caitlyn MurphySenior Vice President and Chief Financial Officercmurphy@burnsmc.com information@savient.com

(212) 213-0006(732) 418-9300
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
2. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
3. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
4. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Savient Pharmaceuticals Adopts Stockholder Rights Plan
6. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
7. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
8. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
9. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
(Date:6/23/2016)... , June 23, 2016  The National ... has joined the health policy research organization as ... Romano , MD, senior vice president and chief ... company,s representative on the NPC Board of Directors. ... pleased that Mallinckrodt has joined us in support ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):